SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rejko Krüger, Rüdiger Hilker, Christian Winkler, Michael Lorrain, Matthias Hahne, Christoph Redecker, Paul Lingor, Wolfgang H. Jost, Advanced stages of PD: interventional therapies and related patient-centered care, Journal of Neural Transmission, 2016, 123, 1, 31

    CrossRef

  2. 2
    Diego Santos García, Juan Carlos Martínez Castrillo, Víctor Puente Périz, Agustín Seoane Urgorri, Servando Fernández Díez, Vicente Benita León, Beatriz Udaeta Baldivieso, Antonia Campolongo Perillo, Natividad Mariscal Pérez, Clinical management of patients with advanced Parkinson’s disease treated with continuous intestinal infusion of levodopa/carbidopa, Neurodegenerative Disease Management, 2016,

    CrossRef

  3. 3
    J. Timpka, T. Fox, K. Fox, H. Honig, P. Odin, P. Martinez-Martin, A. Antonini, K. Ray Chaudhuri, Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease, Acta Neurologica Scandinavica, 2016, 133, 6
  4. 4
    Anthony E. Lang, Ramon L. Rodriguez, James T. Boyd, Sylvain Chouinard, Cindy Zadikoff, Alberto J. Espay, John T. Slevin, Hubert H. Fernandez, Mark F. Lew, David A. Stein, Per Odin, Victor S.C. Fung, Fabian Klostermann, Alfonso Fasano, Peter V. Draganov, Nathan Schmulewitz, Weining Z. Robieson, Susan Eaton, Krai Chatamra, Janet A. Benesh, Jordan Dubow, Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials, Movement Disorders, 2016, 31, 4
  5. 5
    M. Vérin, Que faire au stade évolué des fluctuations ?, Pratique Neurologique - FMC, 2016, 7, 2, 131

    CrossRef

  6. 6
    O. Băjenaru, A. Ene, B. O. Popescu, J. A. Szász, M. Sabău, D. F. Mureşan, L. Perju-Dumbrava, C. D. Popescu, A. Constantinescu, I. Buraga, M. Simu, The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience, Journal of Neural Transmission, 2016, 123, 4, 407

    CrossRef

  7. 7
    T. Laar, D. Nyholm, R. Nyman, Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease, Acta Neurologica Scandinavica, 2016, 133, 3
  8. 8
    Lauren C Seeberger, Robert A Hauser, Carbidopa levodopa enteral suspension, Expert Opinion on Pharmacotherapy, 2015, 16, 18, 2807

    CrossRef

  9. 9
    P. Odin, K. Ray Chaudhuri, J.T. Slevin, J. Volkmann, E. Dietrichs, P. Martinez-Martin, J.K. Krauss, T. Henriksen, R. Katzenschlager, A. Antonini, O. Rascol, W. Poewe, Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program, Parkinsonism & Related Disorders, 2015, 21, 10, 1133

    CrossRef

  10. 10
    N. V. Titova, E. A. Katunina, Current possibilities of quality of life improvement in the late stages of Parkinson’s disease, Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2015, 115, 3, 94

    CrossRef

  11. 11
    Alexander Alamri, Ismail Ughratdar, Michael Samuel, Keyoumars Ashkan, Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 2003–2013: Where are we another 10 years on?, British Journal of Neurosurgery, 2015, 29, 3, 319

    CrossRef

  12. 12
    Jorik Nonnekes, Anke H Snijders, John G Nutt, Günter Deuschl, Nir Giladi, Bastiaan R Bloem, Freezing of gait: a practical approach to management, The Lancet Neurology, 2015, 14, 7, 768

    CrossRef

  13. 13
    Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, Anthony E. Lang, Victor S.C. Fung, Fabian Klostermann, Mark F. Lew, Per Odin, Malcolm Steiger, Eduard Z. Yakupov, Sylvain Chouinard, Oksana Suchowersky, Jordan Dubow, Coleen M. Hall, Krai Chatamra, Weining Z. Robieson, Janet A. Benesh, Alberto J. Espay, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results, Movement Disorders, 2015, 30, 4
  14. 14
    Oluwadamilola O Ojo, Hubert H Fernandez, Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease, Future Neurology, 2015, 10, 3, 191

    CrossRef

  15. 15
    Maríateresa Buongiorno, Francesca Antonelli, Ana Cámara, Victor Puente, Oriol de Fabregues-Nebot, Jorge Hernandez-Vara, Matilde Calopa, Berta Pascual-Sedano, Antonia Campolongo, Francesc Valldeoriola, Eduardo Tolosa, Jaime Kulisevsky, Maria Jose Martí, Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry, Parkinsonism & Related Disorders, 2015, 21, 8, 871

    CrossRef

  16. 16
    J. Belin, J.L. Houéto, T. Constans, C. Hommet, B. de Toffol, K. Mondon, Particularités gériatriques de la maladie de Parkinson : aspects cliniques et thérapeutiques, Revue Neurologique, 2015, 171, 12, 841

    CrossRef

  17. 17
    Sophie Drapier, Marc Vérin, La maladie de Parkinson, 2015,

    CrossRef

  18. 18
    Marina Senek, Dag Nyholm, Continuous Drug Delivery in Parkinson’s Disease, CNS Drugs, 2014, 28, 1, 19

    CrossRef

  19. 19
    C Warren Olanow, Karl Kieburtz, Per Odin, Alberto J Espay, David G Standaert, Hubert H Fernandez, Arvydas Vanagunas, Ahmed A Othman, Katherine L Widnell, Weining Z Robieson, Yili Pritchett, Krai Chatamra, Janet Benesh, Robert A Lenz, Angelo Antonini, Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study, The Lancet Neurology, 2014, 13, 2, 141

    CrossRef

  20. 20
    Mariachiara Sensi, F. Preda, L. Trevisani, E. Contini, D. Gragnaniello, J. G. Capone, E. Sette, N. Golfre-Andreasi, V. Tugnoli, M. R. Tola, R. Quatrale, Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients, Journal of Neural Transmission, 2014, 121, 6, 633

    CrossRef

  21. 21
    F.I. Tarazi, Z.T. Sahli, M. Wolny, S.A. Mousa, Emerging therapies for Parkinson's disease: From bench to bedside, Pharmacology & Therapeutics, 2014, 144, 2, 123

    CrossRef

  22. 22
    Guoxin Zhang, Zhentao Zhang, Ling Liu, Jiaolong Yang, Jinsha Huang, Nian Xiong, Tao Wang, Impulsive and Compulsive Behaviors in Parkinson’s Disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  23. 23
    M. Zibetti, A. Merola, C. A. Artusi, L. Rizzi, S. Angrisano, D. Reggio, C. Angelis, M. Rizzone, L. Lopiano, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, European Journal of Neurology, 2014, 21, 2
  24. 24
    Livia Dézsi, László Vécsei, Safinamide for the treatment of Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 5, 729

    CrossRef

  25. 25
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  26. 26
    Monika Pötter-Nerger, Peter Ludewig, Ute Hidding, Ines Goerendt, Christian Gerloff, Carsten Buhmann, Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?, InFo Neurologie & Psychiatrie, 2014, 16, 12, 42

    CrossRef

  27. 27
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  28. 28
    Qing Lv, Baorong Zhang, Application of the concept of continuous dopaminergic stimulation for the management of Parkinson’s disease, Neuroscience Bulletin, 2013, 29, 5, 661

    CrossRef

  29. 29
    C. Moreau, A. Annic, D. Devos, L. Defebvre, Comment gérer un traitement par Duodopa® dans la maladie de Parkinson évoluée ?, Pratique Neurologique - FMC, 2013, 4, 1, 22

    CrossRef

  30. 30
    Brenton A Wright, Cheryl H Waters, Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 719

    CrossRef

  31. 31
    A. Antonini, P. Odin, L. opiano, V. Tomantschger, C. Pacchetti, B. Pickut, U. E. Gasser, D. Calandrella, F. Mancini, M. Zibetti, B. Minafra, I. Bertaina, P. De Deyn, C. Cras, E. Wolf, S. Spielberger, W. Poewe, Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care, Journal of Neural Transmission, 2013, 120, 11, 1553

    CrossRef

  32. 32
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  33. 33
    T. Foltynie, C. Magee, C. James, G. J. M. Webster, A. J. Lees, P. Limousin, Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series, Parkinson's Disease, 2013, 2013, 1

    CrossRef

  34. 34
    Barbara Anne Pickut, Chris van der Linden, Sophie Dethy, Hilde Van De Maele, Diederik Zegers de Beyl, Intestinal levodopa infusion: the Belgian experience, Neurological Sciences, 2013,

    CrossRef

  35. 35
    María José Catalán, Eduardo Pablo-Fernández, Clara Villanueva, Servando Fernández-Diez, Teresa Lapeña-Montero, Rocío García-Ramos, Eva López-Valdés, Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease, Movement Disorders, 2013, 28, 14
  36. 36
    Hubert H. Fernandez, Arvydas Vanagunas, Per Odin, Alberto J. Espay, Robert A. Hauser, David G. Standaert, Krai Chatamra, Janet Benesh, Yili Pritchett, Steven L. Hass, Robert A. Lenz, Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results, Parkinsonism & Related Disorders, 2013, 19, 3, 339

    CrossRef

  37. 37
    Maurizio Zibetti, Aristide Merola, Valeria Ricchi, Alice Marchisio, Carlo Alberto Artusi, Laura Rizzi, Elisa Montanaro, Dario Reggio, Claudio Angelis, Mario Rizzone, Leonardo Lopiano, Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study, Journal of Neurology, 2013, 260, 1, 105

    CrossRef

  38. 38
    Fabienne Sprenger, Werner Poewe, Management of Motor and Non-Motor Symptoms in Parkinson’s Disease, CNS Drugs, 2013, 27, 4, 259

    CrossRef

  39. 39
    David Devos, Caroline Moreau, Kathy Dujardin, Ioav Cabantchik, Luc Defebvre, Regis Bordet, New Pharmacological Options for Treating Advanced Parkinson’s Disease, Clinical Therapeutics, 2013, 35, 10, 1640

    CrossRef

  40. 40
    Thomas Müller, Teus van Laar, David R. Cornblath, Per Odin, Fabian Klostermann, Francisco J. Grandas, Georg Ebersbach, Peter P. Urban, Francesc Valldeoriola, Angelo Antonini, Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery, Parkinsonism & Related Disorders, 2013, 19, 5, 501

    CrossRef

  41. 41
    Samuel D. Kim, Natalie E. Allen, Colleen G. Canning, Victor S. C. Fung, Postural Instability in Patients with Parkinson’s Disease, CNS Drugs, 2013, 27, 2, 97

    CrossRef

  42. 42
    Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas, Michael D. Bentley, Zhihao Fang, Bekir Dizman, Kunsang Yoon, Rebecca Weimer, Paula Ravenscroft, Tom H. Johnston, Michael P. Hill, Jonathan M. Brotchie, Randall W. Moreadith, Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit, Movement Disorders, 2013, 28, 12
  43. 43
    Jens Volkmann, Alberto Albanese, Angelo Antonini, K. Ray Chaudhuri, Carl E. Clarke, Rob M. A. Bie, Günther Deuschl, Karla Eggert, Jean-Luc Houeto, Jaime Kulisevsky, Dag Nyholm, Per Odin, Karen Østergaard, Werner Poewe, Pierre Pollak, Jose Martin Rabey, Olivier Rascol, Evzen Ruzicka, Michael Samuel, Hans Speelman, Olof Sydow, Francesc Valldeoriola, Chris Linden, Wolfgang Oertel, Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review, Journal of Neurology, 2013, 260, 11, 2701

    CrossRef

  44. You have free access to this content44
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  45. 45
    Fernando Pagan, Jill Farmer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  46. 46
    Fernando L. Pagan, Jill Giordano Farmer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  47. 47
    Yoshikuni Mizuno, An update on the management of juvenile and young-onset Parkinson’s disease, Future Neurology, 2012, 7, 5, 581

    CrossRef

  48. 48
    Anders Johansson, Dag Nyholm, Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa–carbidopa intestinal gel in the absence of head-to-head comparisons, Basal Ganglia, 2012, 2, 4, 221

    CrossRef

  49. 49
    Dag Nyholm, Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety, Parkinsonism & Related Disorders, 2012, 18, 8, 916

    CrossRef

  50. 50
    Yoshikuni Mizuno, Mitsutoshi Yamamoto, Sadako Kuno, Kazuko Hasegawa, Nobutaka Hattori, Tatsuro Kagimura, Akiko Sarashina, Olivier Rascol, Anthony H.V. Schapira, Paolo Barone, Robert A. Hauser, Werner Poewe, Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease, Clinical Neuropharmacology, 2012, 35, 4, 174

    CrossRef

  51. 51
    S. E. Pålhagen, N. Dizdar, T. Hauge, B. Holmberg, R. Jansson, J. Linder, D. Nyholm, O. Sydow, M. Wainwright, H. Widner, A. Johansson, Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease, Acta Neurologica Scandinavica, 2012, 126, 6
  52. 52
    D. Nyholm, K. Klangemo, A. Johansson, Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease, European Journal of Neurology, 2012, 19, 8
  53. 53
    A. E. Elia, C. Dollenz, P. Soliveri, A. Albanese, Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation, European Journal of Neurology, 2012, 19, 1
  54. 54
    E. Roze, Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ?, Les cahiers de l'année gérontologique, 2012, 4, 2, 50

    CrossRef

  55. 55
    John Goudreau, J Ahlskog, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  56. 56
    C. Schrader, S. Böselt, J. Wedemeyer, D. Dressler, T.J. Weismüller, Asparagus and jejunal-through-PEG: An unhappy encounter in intrajejunal levodopa infusion therapy, Parkinsonism & Related Disorders, 2011, 17, 1, 67

    CrossRef

  57. 57
    Fabian Klostermann, Constanze Jugel, Frank Marzinzik, Benefit from jejunal levodopa in a patient with apomorphine pump, Journal of Neurology, 2011, 258, 2, 311

    CrossRef

  58. 58
    Aristide Merola, Maurizio Zibetti, Serena Angrisano, Laura Rizzi, Michele Lanotte, Leonardo Lopiano, Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease, Movement Disorders, 2011, 26, 4
  59. 59
    P. Jenner, A. C. McCreary, D. K. A. Scheller, Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression, Journal of Neural Transmission, 2011, 118, 12, 1691

    CrossRef

  60. 60
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, sup2, 53

    CrossRef

  61. 61
    H.H. Fernandez, P. Odin, Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease, Current Medical Research and Opinion, 2011, 27, 5, 907

    CrossRef

  62. 62
    S. L. Jones, J. V. Hindle, Parkinson's disease in the acute hospital, Clinical Medicine, 2011, 11, 1, 84

    CrossRef

  63. 63
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  64. 64
    Mildred D. Gottwald, Michael J. Aminoff, Therapies for dopaminergic-induced dyskinesias in parkinson disease, Annals of Neurology, 2011, 69, 6
  65. 65
    Anne Marthe Meppelink, Rickard Nyman, Teus van Laar, Martje Drent, Ted Prins, Klaus Leonhard Leenders, Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease, Movement Disorders, 2011, 26, 2
  66. 66
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  67. 67
    Rüdiger Hilker, Angelo Antonini, Per Odin, What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?, Journal of Neural Transmission, 2011, 118, 6, 907

    CrossRef

  68. 68
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  69. 69
    Juan Carlos Gómez Esteban, Neurofarmacología Contemporánea, 2011,

    CrossRef

  70. 70
    L.K. Prashanth, Susan Fox, Wassilios G. Meissner, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  71. 71
    M. Vérin, La maladie de Parkinson, 2011,

    CrossRef

  72. 72
    Andrzej Bogucki, Jarosław Sławek, Ciągła stymulacja dopaminergiczna – doświadczenia kliniczne, Neurologia i Neurochirurgia Polska, 2010, 44, 4, 385

    CrossRef

  73. 73
    Cristina Sánchez-Castañeda, Jaume Campdelacreu, Júlia Miró, Montse Juncadella, Serge Jaumà, Màtil Calopa, Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1, 250

    CrossRef

  74. 74
    Jarosław Sławek, Andrzej Bogucki, Dojelitowa postać lewodopy w leczeniu zaawansowanej choroby Parkinsona, Neurologia i Neurochirurgia Polska, 2010, 44, 4, 396

    CrossRef

  75. 75
    David Devos, L. Defebvre, R. Bordet, Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease, Fundamental & Clinical Pharmacology, 2010, 24, 4
  76. 76
    D. Santos-García, M. Macías, M. Llaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte, S. Blanco, Experience with continuous levodopa enteral infusion (Duodopa®)in patients with advanced Parkinson's disease in a secondary level hospital, Neurología (English Edition), 2010, 25, 9, 536

    CrossRef

  77. 77
    D. Devos, R. Bordet, L. Defebvre, Hypothèses pharmacologiques et prise en charge thérapeutique des troubles de la marche de la maladie de Parkinson, Revue Neurologique, 2010, 166, 2, 168

    CrossRef

  78. 78
    Alberto J. Espay, Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies, Neurologic Clinics, 2010, 28, 4, 913

    CrossRef

  79. 79
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  80. 80
    Sara Varanese, Zoe Birnbaum, Roger Rossi, Alessandro Di Rocco, Treatment of Advanced Parkinson's Disease, Parkinson's Disease, 2010, 2010, 1

    CrossRef

  81. 81
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2009, 18, 12
  82. 82
    Nancy L Diaz, Cheryl H Waters, Current strategies in the treatment of Parkinson’s disease and a personalized approach to management, Expert Review of Neurotherapeutics, 2009, 9, 12, 1781

    CrossRef

  83. 83
    Angelo Antonini, Per Odin, Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S97

    CrossRef

  84. 84
    Diego Santos-García, Mercedes Macías, Miguel Llaneza, Ángel Aneiros, Suicide following duodenal levodopa infusion for Parkinson's disease, Movement Disorders, 2009, 24, 13
  85. 85
    Carl E. Clarke, Paul Worth, Donald Grosset, David Stewart, Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, 10, 728

    CrossRef

  86. 86
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,